Lehman ABS Corporation (NYSE: BMY)

Sector: Medical

Current Price : $46.60

52 Week Low
$30.8152 Week High
$46.60

Technicals

Press Releases
Start Making Profits Now With AMAT, BMY, GILD and RENN
In the Know, Smart Investing in QQQ, NBG and BMY
Bristol-Myers Squibb Announces Intention to Voluntarily Delist Preferred Stock
Start Making Profits Now With MSFT, BMY and INTC
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
Bristol-Myers Squibb Advances Leadership Position in Immuno-Oncology with Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
In the Know, Smart Investing in FCX, GILD, AIG and BMY
Bristol-Myers Squibb to Present at UBS Global Health Care Conference
The Straight Truth, Investing in NVDA, BMY and WAG
Strategy Behind Our Success, We Get in Early: PEP, LTD, CMG and BMY
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Health Care Conference
Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation
Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Period
Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA? (efavirenz) in HIV-1 Infected Pediatric Patients
Key to Success, How to Profit: GILD, BMY, EBAY and FFIV
Bristol-Myers Squibb Reports First Quarter 2013 Financial Results
Former Pro Football Coach Bill Cowher Tells Men "No Excuses" When It Comes to Getting Screened for Melanoma
High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Na?ve Patients with Genotype 1 Chronic Hepatitis C Infection
Bristol-Myers Squibb Funds Green Schools Fellowship to Help New Jersey School Districts Create Healthier, More Sustainable Learning Environments
Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for RNA-targeted medicines
Perfect Trade Setups, How to Play COH, BMY, CELG and CLF
The Real Story Behind NOK, UTX, CELG and BMY
Bristol-Myers Squibb to Expand Massachusetts Biologics Facility
Bristol-Myers Squibb Foundation, Morehouse School of Medicine Partner to Spread Lessons from Together on Diabetes(TM) Initiative
Bristol-Myers Squibb to Present New Data on Hepatitis C and Hepatitis B Compounds at The International Liver CongressTM (ILC) 2013
Bristol-Myers Squibb Announces Appointment of Francis Cuss as Executive Vice President and Chief Scientific Officer, Effective July 1; Elliott Sigal Plans to Retire
Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles for Recoupment Policies Covering Major Compliance Failures
Bristol-Myers Squibb to Announce Results for First Quarter 2013 on April 25
Today's Analysis on Bristol-Myers Squibb, Eli Lilly & Co., Endo Pharma, and Allergan
Before the Crowd, How We Found AMD, AMAT, BMY and RDN
The Real Story Behind PEP, JPM, BMY and MDLZ
Perfect Trade Setups, How to Play CVS, BMY, COP and LVS
Improving Lives: Breakthroughs & Collaborations - Research Report on Pfizer, Merck, Bristol-Myers Squibb, J&J and Lilly
Were You in Early on BMY, PEP, NWSA and PCLN
A Forward Look, the Year Ahead - Research Report on Amgen, Inc., Bristol Myers Squibb Co., Ann Inc., Limited Brands, Inc. and AMETEK, Inc.
Bristol-Myers Squibb Awards Two Grants to Support Comprehensive Cancer Community Collaboration at Several Hospitals in New Jersey
Bristol-Myers Squibb Announces Dividend
Bristol-Myers Squibb to Present at Barclays Global Health Care Conference
Next Week's Trade Setups, What's in Store for IBM, MO, NEM and BMY
The Real Story Behind VNO, BMY, EXPE and STJ
Factors Moving Markets- Research Report on Actavis, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Gilead Sciences Inc. and Novo Nordisk
Bristol-Myers Squibb to Present at Cowen and Company Health Care Conference
A New Direction, What's Ahead - Research Report on Newmont Mining Corp, AMETEK, Inc., Honeywell International Inc., Amgen, Inc. and Bristol Myers Squibb Co.
Bristol-Myers Squibb to Take Part in Citi 2013 Global Health Care Conference
Earnings Help Fuel S&P 500 Index Rally -- S&P 500 Index Tops 1500 Mark for the First Time in 5 Years
Leading Pharmaceutical Companies Mid-day Trading with Mixed Results and also New Patent News Announced for Crown Marketing
Bristol-Myers Squibb Appoints Ann Powell Judge Senior Vice President, Human Resources
Bristol-Myers Squibb Enters a Collaboration Agreement for Several Over-the-Counter Medicines with Reckitt Benckiser Group plc
Should Recent Insider Selling on BMY, GOOG, UNM and MDC Matter to You?
Did You Miss CBS, BMY, and NTAP
Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference
Free Research Report on BP Plc, Bristol-Myers Squibb Co., Aetna, Inc. and Analog Devices, Inc.
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2012 Financial Results
Bristol-Myers Squibb Appoints Mike Burgess M.D., Ph.D. Senior Vice President, Discovery Medicine and Clinical Pharmacology
ERBITUX? in combination with chemotherapy approved in Canada as initial treatment of patients with metastatic colorectal cancer
OPKO Health Expands Collaboration with Bristol-Myers Squibb
Perfect Trade Setups, How to Play CELG, NVS, GSK and BMY
The Real Story Behind ISIS, BIIB, NWBO and BMY
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2012 on January 24
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS? (apixaban)
ELIQUIS? (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation
Innate Pharma: Phase I Clinical Trial of IPH2102/BMS-986015 in Combination With Ipilimumab Announced
Innate Pharma (Euronext Paris: FR0010331421 - IPH): First Patient Treated in the EffiKIR Trial
The Medicines Company and Bristol-Myers Squibb Agree to Global Alliance for Recothrom(R)
Elotuzumab Progression-Free Survival Data from Phase 2 Study of Patients with Previously-Treated Multiple Myeloma Presented at 54th American Society of Hematology (ASH) Annual Meeting
ELIQUIS? (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One Year Of Extended Treatment
Bristol-Myers Squibb Launches an Online Resource for Patients with Chronic Myeloid Leukaemia in 15 European Countries
One-in-Four Canadians Over 40 Will Suffer From Atrial Fibrillation in Their Life Time(1)
Bristol-Myers Squibb Announces Dividend Increase
ELIQUIS?(apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
Forxiga(tm) (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes
Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 Achieved SVR12 of 94% in Treatment-Na?ve Patients with Genotype 1 Chronic Hepatitis C Infection in Phase II Trial
Bristol-Myers Squibb's Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study
Investigational Hepatitis C Dual DAA Regimen of Daclatasvir and Asunaprevir Achieved SVR12 in 78% of Difficult-to-Treat Genotype 1b Prior Null Responders In Expanded Phase II Study
Investigational Hepatitis C Quad Therapy Regimen of Daclatasvir and Asunaprevir Plus Interferon Alfa and Ribavirin Achieved SVR24 in 93% of Difficult-to-Treat Genotype 1a/b Prior Null Responders in Expanded Phase II Study
Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference
Bristol-Myers Squibb Foundation Announces Centers of Excellence Conference to Share Insights from Asian-Pacific Community Groups on Viral Hepatitis Management in Honor of the 10-Year Anniversary of Delivering Hope(tm)
European Commission Approves Labelling Update for BARACLUDE? (entecavir) in Liver Transplant Patients with Chronic Hepatitis B
Bristol-Myers Squibb and Pfizer Announce New Data on Stroke Prevention in Atrial Fibrillation to be Presented at American Heart Association 2012 Scientific Sessions
Bristol-Myers Squibb Receives Positive Decision from National Institute of Health and Clinical Excellence (NICE) for YERVOY? (ipilimumab)
Where We Are Headed -- New Outlook on Bristol-Myers Squibb Company and AstraZeneca Plc
Bristol-Myers Squibb to Present New Data Demonstrating Company's Continuing Commitment to Research and Development in Liver Disease at The American Association for the Study of Liver Diseases (AASLD) Annual Meeting
U.S. Food and Drug Administration Approves Labeling Update for BARACLUDE? (entecavir) (0.5 mg/1 mg Tablets) to Include Data on African Americans and Liver Transplant Recipients with Chronic Hepatitis B in Adult Patients
Subcutaneous Formulation of ORENCIA? (abatacept) Approved by European Commission
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
ELIQUIS? (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at Varying Risk for Stroke and Bleeding
Bristol-Myers Squibb to Announce Results for Third Quarter on October 24
New Four- and Five-Year Survival Data for YERVOY? (ipilimumab) in Treatment-Na?ve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology)
Bristol-Myers Squibb Appoints Frances Heller Senior Vice President, Business Development
FDA Acknowledges Receipt of Resubmission of the ELIQUIS? (apixaban) New Drug Application to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
Major Pharmaceutical Stocks Rise After Moody's Upgrades Industry to "Stable"
Bristol-Myers Squibb Foundation Celebrates Hispanic Heritage Month
ELIQUIS? (apixaban) Receives CHMP Positive Opinion For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation
Vanderbilt University and Bristol-Myers Squibb Sign Collaboration Agreement to Develop Novel Treatments for Parkinson's Disease
Bristol-Myers Squibb Announces Dividend
Life Technologies to Partner with Bristol-Myers Squibb for Companion Diagnostics Development
Bristol-Myers Squibb to Present at UBS Global Life Sciences Conference
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
A Refreshing Outlook - Consensus Reports on Pfizer, Inc. and Bristol-Myers Squibb Company

iStock Rating

Lehman ABS Corporation (NYSE: BMY)

Sector: Medical

Company

Community

Analysis

Charts

Analyst

Ratios